<DOC>
	<DOCNO>NCT00831714</DOCNO>
	<brief_summary>The main goal provide additional information risk-benefit assessment drug .</brief_summary>
	<brief_title>Xarelto VTE Prophylaxis After Hip Knee Arthroplasty</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Female male patient undergo elective hip knee arthroplasty . Exclusion criterion must read conjunction local product information .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Prophylaxis Venous Thromboembolism</keyword>
</DOC>